NASDAQ:GPCR

Structure Therapeutics (GPCR) Stock Price, News & Analysis

Structure Therapeutics logo
$16.96 -0.40 (-2.28%)
As of 11:18 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Structure Therapeutics Stock (NASDAQ:GPCR)

Advanced

Key Stats

Today's Range
$16.97
▼
$17.95
50-Day Range
$17.36
▼
$39.55
52-Week Range
$16.97
▼
$94.90
Volume
141,322 shs
Average Volume
965,002 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.91
Consensus Rating
Moderate Buy

Company Overview

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates.

The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

Founded in 2016, the company has operations in the United States and China. Raymond Stevens, Ph.D., a co-founder of the company, serves as its chief executive officer.

AI Generated. May Contain Errors.

Structure Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

GPCR MarketRank™: 
3.52832512315 of 5 stars

Structure Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 713th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Structure Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 2 strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Structure Therapeutics has a consensus price target of $110.91, representing about 538.9% upside from its current price of $17.36.

  • Amount of Analyst Coverage

    Structure Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Structure Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Structure Therapeutics are expected to decrease in the coming year, from ($2.14) to ($2.44) per share.

  • Price to Book Value per Share Ratio

    Structure Therapeutics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.01% of the float of Structure Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Structure Therapeutics has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Structure Therapeutics has recently decreased by 17.07%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Structure Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Structure Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Structure Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Structure Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    12 people have searched for GPCR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Structure Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.50% of the stock of Structure Therapeutics is held by insiders.

  • Percentage Held by Institutions

    91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Structure Therapeutics' insider trading history.
Receive GPCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GPCR Stock News Headlines

HC Wainwright Has Negative Opinion of GPCR FY2026 Earnings
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Analysts Offer Predictions for GPCR Q1 Earnings
See More Headlines

GPCR Stock Analysis - Frequently Asked Questions

Structure Therapeutics' stock was trading at $69.55 at the beginning of the year. Since then, GPCR shares have decreased by 75.0% and is now trading at $17.36.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) released its quarterly earnings data on Monday, November, 9th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.15.

Structure Therapeutics (GPCR) raised $150 million in an IPO on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share.

Top institutional investors of Structure Therapeutics include B Group Inc. (0.26%), HighVista Strategies LLC (0.24%), Healthcare of Ontario Pension Plan Trust Fund (0.19%) and Jefferies Financial Group Inc. (0.18%).

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Palantir Technologies (PLTR), SoundHound AI (SOUN), Viking Therapeutics (VKTX), SLB (SLB) and Symbotic (SYM).

Company Calendar

Last Earnings
11/09/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:GPCR
CIK
1888886
Fax
N/A
Employees
281
Year Founded
N/A

Price Target and Rating

High Price Target
$145.00
Low Price Target
$70.00
Potential Upside/Downside
+544.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$141.20 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-29.18%
Return on Assets
-27.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.90
Quick Ratio
11.91

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$17.45 per share
Price / Book
0.99

Miscellaneous

Outstanding Shares
70,030,000
Free Float
66,178,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
-1.12
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:GPCR) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners